Le dépistage: pour une réelle liberté de choix

Octobre Rose mot à maux, Rachel Campergue

Présentation de l’éditeur

Octobre rose mot à maux, book cover image
Lisez ce livre, et “vous ne verrez plus jamais les slogans d’Octobre rose de la même façon”, nous dit Rachel Campergue.
  • Se faire dépister ou pas ?
  • Comment prendre la bonne décision ? La décision qui vous convient le mieux ?
  • Qui croire ? Qui écouter ? En premier lieu vous.
  • Mais qui est ce “vous” qui décide ? Est-ce bien lui qui décide ? N’a-t-il pas été trompé en amont ? Trompé par des mots qu’il emploie quotidiennement pour échanger avec ses semblables, mais qui auront été utilisés par d’autres, non pour échanger, mais pour manipuler. Des mots employés à contresens pour leur charge positive, des mots que ce “vous” qui croit décider laisse passer sans méfiance et dès lors, ce n’est déjà plus lui qui décide : il y a eu manipulation. Á chaque fois qu’il y a rétention d’information ou emploi à contresens des mots, vous n’avez pas choisi : on a choisi pour vous, tout en vous laissant l’illusion du choix. Imparable car invisible.
  • Comment résister ? Avec quels outils ?

Ce livre vous en procure quelques uns. Lisez-le, et vous ne verrez plus jamais les slogans d’Octobre rose de la même façon.

Á propos de l’auteure

Rachel Campergue exerce quatorze ans le métier de kinésithérapeute, principalement à Moorea et Tahiti, avant de partir filmer les requins sur l’atoll de Rangiroa, en Polynésie française, pendant dix ans. Un documentaire en naît, dénonçant la pratique du shark finning. En 2009, elle lâche la caméra pour l’écriture et publie en 2011 “No Mammo ? Enquête sur le dépistage du cancer du sein” – voir commentaires en ligne – aux éditions Max Milo. Elle partage aujourd’hui son temps entre les Cévennes et le Costa Rica.

En savoir plus:
  • Présentation du livre, par Rachel sur expertise citoyenne – Rachel sur Twitter.
  • Quand les mots perdent leur sens, les gens perdent leur liberté, Formindep, oct 2014.
  • Commentaires d’acheteurs sur Amazon.

Payton v. Abbott Laboratories: an analysis of the Massachusetts DES class action suit

A landmark ruling for plaintiffs seeking class certification in DES suits

image of PubMed NCBI The Endocrine Society logo
The first case in which a judge has interpreted the requirements of Rule 23 of the Federal Rules of Civil Procedure to allow women exposed in utero to DES to sue as a class to determine liability for their injuries

In Payton v. Abbott Laboratories, U.S. District Court Judge Walter J. Skinner recently granted class certification to an action brought by twenty-seven Massachusetts women against major manufacturers of DES.
This is the first case in which a judge has interpreted the requirements of Rule 23 of the Federal Rules of Civil Procedure to allow women exposed in utero to DES to sue as a class to determine liability for their injuries.

  • This Note reviews the Payton certification in light of prior class action decisions involving DES and other types of claims, and of legal commentary on Rule 23.
  • This Note contends that Judge Skinner’s application of the Rule 23 requirements in Payton was procedurally correct, and recommends the class action device as an effective method for litigating such controversies.
  • Finally, this Note analyzes the implication of this landmark ruling for plaintiffs seeking class certification in DES suits and in suits presenting analogous factual situations.

Sources

  • Payton v. Abbott Laboratories: an analysis of the Massachusetts DES class action suit, NCBI, PMID: 7468600, 1980 Summer;6(2):243-82.
  • Full text on HeinOnline.
More DES DiEthylStilbestrol Resources

I went to an egg freezing cocktail party so you don’t have to…

Marketing egg freezing technology for the purpose of deferring childbearing may give women false hope and encourage women to delay childbearing

EggBanxx facebook cover image
EggBanxx cover image on Facebook…
actually, I tend to agree with them ; I did freeze when I saw this advert and their events promo…

” At an event hosted by EggBanxx, women came to drink free wine and learn about egg freezing, something their hosts were promoting as a way to stop the biological clock so they can have their babies later…

  • They were preying on women’s insecurities, kind of like the plastic surgery business…
  • These stats don’t jibe with the most recent peer-reviewed study of success rates after egg freezing. “

Read Should You Freeze Your Eggs? by Robin Marantz Henig,
on Slate, Sept. 30 2014.

… ” Marketing this technology for the purpose of deferring childbearing may give women false hope and encourage women to delay childbearing. In particular, there is concern regarding the success rates in women in the late reproductive years who may be the most interested in this application. …  Patients who wish to pursue this technology should be carefully counseled about age and clinic-specific success rates of oocyte cryopreservation vs. conceiving on her own and risks, costs, and alternatives to using this approach. ” …

More Information:
  • Mature oocyte cryopreservation: a guideline, Fertility and Sterility, January 2013.
  • Mature oocyte cryopreservation: a guideline, ASSM, January 2013.

Could Immunotherapy Stop Resistance to Radiotherapy?

Doctors and researchers are constantly looking for ways to improve treatments

Cancer Research UK
This approach could open the door to a whole new way of giving radiotherapy.

Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment, according to a study published in Cancer Research.

The researchers, based at The University of Manchester and funded by Cancer Research UK and MedImmune found that combining the two treatments helped the immune system hunt down and destroy cancer cells that were not killed by the initial radiotherapy in mice with breast, skin and bowel cancers.

Sources and more information:

  • Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade, Cancer Research,  October 1, 2014 74;5458.
  • Immunotherapy could stop resistance to radiotherapy, Cancer Research UK Press release, 1 October 2014.